|
業務類別
|
Biotechnology |
|
業務概覽
|
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K. |
| 公司地址
| 22722 29th Drive SE, Suite 100, Bothell, WA, USA, 98021 |
| 電話號碼
| +1 604 210-2217 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.achievelifesciences.com |
| 員工數量
| 28 |
| Mr. Mark K. Oki |
Chief Financial Officer |
美元 30.86K |
24/03/2026 |
| Dr. Andrew Goldberg, M.D. |
Chief Executive Officer, President and Director |
-- |
16/04/2026 |
| Ms. Jaime Xinos |
Chief Commercial Officer |
-- |
28/04/2025 |
| Mr. Jerry Wan |
Principal Accounting Officer and Vice President, Finance |
-- |
24/03/2026 |
|
|
| Ms. Nancy R. Phelan |
Director |
24/03/2026 |
| Mr. Richard Alistair Balfour Stewart |
Director |
16/04/2026 |
| Mr. Stuart M. Duty |
Independent Director |
24/03/2026 |
| Mr. Thomas Braxton King |
Interim Executive Chairman of the Board |
24/03/2026 |
| Dr. Andrew Goldberg, M.D. |
Chief Executive Officer, President and Director |
16/04/2026 |
| Dr. Bridget A. Martell, M.D. |
Independent Director |
24/03/2026 |
| Mr. Thomas Sellig |
Independent Director |
24/03/2026 |
| Dr. Kristin Slaoui, PhD |
Independent Director |
24/03/2026 |
|
|
|
|
